Tirzepatide 10mg

Tirzepatide Peptide

Tirzepatide is a synthetic, 39-amino acid unimolecular peptide that acts as a dual agonist, targeting two key metabolic receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. It is engineered as a “twincretin,” designed to harness the synergistic effects of both incretin hormones to manage metabolic dysfunction more effectively than selective GLP-1 agonists alone.

The structure of Tirzepatide is based on the native GIP sequence but includes significant modifications to enhance its stability and potency. Specifically, it contains a C20 fatty acid diacid moiety attached via a linker to the lysine residue at position 20. This structural modification facilitates high-affinity binding to albumin, extending its half-life to approximately five days. This pharmacokinetic profile supports a once-weekly dosing schedule in clinical and research settings.

---

Overview

Tirzepatide represents a shift in metabolic research by prioritizing the GIP receptor alongside the GLP-1 receptor. While GLP-1 is well-known for its role in glucose-dependent insulin secretion and gastric emptying delay, GIP is believed to play a critical role in lipid metabolism and buffering the common gastrointestinal side effects associated with GLP-1 agonism.

In research models, the dual activation of these pathways appears to create a more robust response in both glycemic control and adipose tissue regulation. By activating the GIP receptor, Tirzepatide may improve insulin sensitivity and increase the metabolic efficiency of white adipose tissue, complementing the appetite-suppressing effects of the GLP-1 component.

---

Chemical Makeup

• Molecular Formula: C225​H348​N48​O68​
• Molecular Weight: 4813.45 g/mol
• Other Known Titles: LY3298176, GIP/GLP-1 receptor agonist

---

Research Studies and Clinical Trials

Tirzepatide and Body Mass Regulation

In the landmark SURMOUNT-1 Phase 3 clinical trial, researchers evaluated the efficacy of Tirzepatide in participants with obesity or overweight. Over a 72-week period, subjects receiving the highest dose (15 mg) achieved a mean weight reduction of 20.9%, compared to 3.1% in the placebo group. This data suggests that the integration of GIP receptor agonism significantly enhances the weight-reductive potential beyond what is typically observed with monotherapy GLP-1 agonists.

Impact on Glycaemic Control and Insulin Sensitivity

The SURPASS clinical trial program investigated Tirzepatide’s impact on Type 2 Diabetes. Results consistently demonstrated superior reductions in HbA1c levels compared to insulin glargine, semaglutide, and placebo. Many participants achieved an HbA1c level of less than 5.7% (the threshold for normoglycemia). Scientists attribute this to the dual-acting mechanism, which optimizes the “incretin effect” and improves the function of pancreatic beta cells.

Tirzepatide and Hepatic Lipid Content

Sub-studies utilizing MRI technology have explored Tirzepatide’s effect on liver fat. In subjects with metabolic-associated fatty liver disease, Tirzepatide was shown to reduce liver fat content by nearly 40% relative to baseline. This reduction is theorized to be a result of both direct GIP action on lipid metabolism and the systemic metabolic improvements following significant weight loss.

Cardiovascular and Metabolic Observations

Ongoing research, such as the SURPASS-CVOT trial, is monitoring the long-term cardiovascular outcomes of Tirzepatide. Preliminary data indicates a favorable profile, including improvements in blood pressure and lipid panels (specifically reductions in triglycerides and VLDL cholesterol). While it does not contain the glucagon component found in Retatrutide, its impact on systemic inflammation and metabolic health remains a primary area of investigation for cardioprotection.

Disclaimer: Tirzepatide is a potent metabolic agent. This description is for informational purposes based on current research data and does not constitute medical advice. Tirzepatide is available for research and laboratory purposes only.